APA (7th ed.) Citation

Lee, D. H., Kim, H. R., Keam, B., Kato, K., Kuboki, Y., Gao, H., . . . Ahn, M. (2023, August). Safety and tolerability of first‐line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma. Cancer Medicine.

Chicago Style (17th ed.) Citation

Lee, Dae Ho, Hye Ryun Kim, Bhumsuk Keam, Ken Kato, Yasutoshi Kuboki, Haiyan Gao, Alejandro Yovine, Scott H. Robbins, and Myung‐Ju Ahn. "Safety and Tolerability of First‐line Durvalumab with Tremelimumab and Chemotherapy in Esophageal Squamous Cell Carcinoma." Cancer Medicine Aug. 2023.

MLA (9th ed.) Citation

Lee, Dae Ho, et al. "Safety and Tolerability of First‐line Durvalumab with Tremelimumab and Chemotherapy in Esophageal Squamous Cell Carcinoma." Cancer Medicine, Aug. 2023.